Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa Study of SR-Exenatide (PT320) in Early Parkinson's Disease
NCT04269642Phase 2Unknown
- Sponsor
- Peptron Inc.
- Start
- Mar 2020
- Primary completion
- Sep 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Presendin in Parkinson's disease (PD), sponsored by Peptron Inc.. Status: unknown.
02
Drugs
Presendin
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04269642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04269642.